Raltegravir: first in class HIV integrase inhibitor
On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resista...
Gespeichert in:
| Veröffentlicht in: | Therapeutics and clinical risk management 2008-04, Vol.4 (2), p.493-500 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 500 |
|---|---|
| container_issue | 2 |
| container_start_page | 493 |
| container_title | Therapeutics and clinical risk management |
| container_volume | 4 |
| creator | Temesgen, Zelalem Siraj, Dawd S |
| description | On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase. |
| doi_str_mv | 10.2147/TCRM.S2268 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2504063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20696837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3918-d436620b9fb8ed1dba293fd9fb928ec27ff8625f64261275344c7d07c5ef83793</originalsourceid><addsrcrecordid>eNp9kUtrGzEQx0VIaRK3l36AYAikENhYGq31yCFQTNMEHArOg96EVivZCuuVI60N-fZVbFM3OUQXzWh-89D8EfpG8DmQkg_uR5Pb8zsAJvbQISFcFIDpn_21zQpGKTtARyk9YVwyKclndEAEByGoPER0opvOTqNe-XjRdz6mru_bvml0Sv3rm8fsrMPJZmvmK9-F-AV9crpJ9uv27qGHq5_3o-ti_PvXzejHuDBUElHUJWUMcCVdJWxN6kqDpK7OrgRhDXDnBIOhYyUwAnxIy9LwGnMztE5QLmkPXW7qLpbV3NbGtl3UjVpEP9fxRQXt1dtI62dqGlYKhrjE-d89NNgUqMPKLqJN6U3y7tWEuSKcQM74vm0Zw_PSpk7NfTK2aXRrwzIpnpfJRJ40k6cfkoCZzCTP4Mk78CksY5sXpyAfCZxmuXrobEOZGFKK1v2blGD1qrJ6VVmtVc7w8f-L2aFbWelfUACiiA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2222927320</pqid></control><display><type>article</type><title>Raltegravir: first in class HIV integrase inhibitor</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Temesgen, Zelalem ; Siraj, Dawd S</creator><creatorcontrib>Temesgen, Zelalem ; Siraj, Dawd S</creatorcontrib><description>On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.</description><identifier>ISSN: 1176-6336</identifier><identifier>ISSN: 1178-203X</identifier><identifier>EISSN: 1178-203X</identifier><identifier>DOI: 10.2147/TCRM.S2268</identifier><identifier>PMID: 18728839</identifier><language>eng</language><publisher>New Zealand: Taylor & Francis Ltd</publisher><subject>antiretroviral agents ; Antiretroviral drugs ; HIV ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; integrase inhibitors ; raltegravir ; Review</subject><ispartof>Therapeutics and clinical risk management, 2008-04, Vol.4 (2), p.493-500</ispartof><rights>2008. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2008 Dove Medical Press Limited. All rights reserved 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3918-d436620b9fb8ed1dba293fd9fb928ec27ff8625f64261275344c7d07c5ef83793</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504063/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504063/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3849,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18728839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temesgen, Zelalem</creatorcontrib><creatorcontrib>Siraj, Dawd S</creatorcontrib><title>Raltegravir: first in class HIV integrase inhibitor</title><title>Therapeutics and clinical risk management</title><addtitle>Ther Clin Risk Manag</addtitle><description>On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.</description><subject>antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>integrase inhibitors</subject><subject>raltegravir</subject><subject>Review</subject><issn>1176-6336</issn><issn>1178-203X</issn><issn>1178-203X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUtrGzEQx0VIaRK3l36AYAikENhYGq31yCFQTNMEHArOg96EVivZCuuVI60N-fZVbFM3OUQXzWh-89D8EfpG8DmQkg_uR5Pb8zsAJvbQISFcFIDpn_21zQpGKTtARyk9YVwyKclndEAEByGoPER0opvOTqNe-XjRdz6mru_bvml0Sv3rm8fsrMPJZmvmK9-F-AV9crpJ9uv27qGHq5_3o-ti_PvXzejHuDBUElHUJWUMcCVdJWxN6kqDpK7OrgRhDXDnBIOhYyUwAnxIy9LwGnMztE5QLmkPXW7qLpbV3NbGtl3UjVpEP9fxRQXt1dtI62dqGlYKhrjE-d89NNgUqMPKLqJN6U3y7tWEuSKcQM74vm0Zw_PSpk7NfTK2aXRrwzIpnpfJRJ40k6cfkoCZzCTP4Mk78CksY5sXpyAfCZxmuXrobEOZGFKK1v2blGD1qrJ6VVmtVc7w8f-L2aFbWelfUACiiA</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Temesgen, Zelalem</creator><creator>Siraj, Dawd S</creator><general>Taylor & Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7U1</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080401</creationdate><title>Raltegravir: first in class HIV integrase inhibitor</title><author>Temesgen, Zelalem ; Siraj, Dawd S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3918-d436620b9fb8ed1dba293fd9fb928ec27ff8625f64261275344c7d07c5ef83793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>integrase inhibitors</topic><topic>raltegravir</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temesgen, Zelalem</creatorcontrib><creatorcontrib>Siraj, Dawd S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Therapeutics and clinical risk management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temesgen, Zelalem</au><au>Siraj, Dawd S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Raltegravir: first in class HIV integrase inhibitor</atitle><jtitle>Therapeutics and clinical risk management</jtitle><addtitle>Ther Clin Risk Manag</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>4</volume><issue>2</issue><spage>493</spage><epage>500</epage><pages>493-500</pages><issn>1176-6336</issn><issn>1178-203X</issn><eissn>1178-203X</eissn><abstract>On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.</abstract><cop>New Zealand</cop><pub>Taylor & Francis Ltd</pub><pmid>18728839</pmid><doi>10.2147/TCRM.S2268</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1176-6336 |
| ispartof | Therapeutics and clinical risk management, 2008-04, Vol.4 (2), p.493-500 |
| issn | 1176-6336 1178-203X 1178-203X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2504063 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | antiretroviral agents Antiretroviral drugs HIV Human immunodeficiency virus Human immunodeficiency virus 1 integrase inhibitors raltegravir Review |
| title | Raltegravir: first in class HIV integrase inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A10%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Raltegravir:%20first%20in%20class%20HIV%20integrase%20inhibitor&rft.jtitle=Therapeutics%20and%20clinical%20risk%20management&rft.au=Temesgen,%20Zelalem&rft.date=2008-04-01&rft.volume=4&rft.issue=2&rft.spage=493&rft.epage=500&rft.pages=493-500&rft.issn=1176-6336&rft.eissn=1178-203X&rft_id=info:doi/10.2147/TCRM.S2268&rft_dat=%3Cproquest_pubme%3E20696837%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2222927320&rft_id=info:pmid/18728839&rfr_iscdi=true |